{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Human+Albumin+Infusion&page=2",
    "query": {
      "intervention": "Human Albumin Infusion",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Human+Albumin+Infusion&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T11:45:01.680Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01376778",
      "title": "A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Congenital Cytomegalovirus Infection",
        "Maternal Cytomegalovirus Infection"
      ],
      "interventions": [
        {
          "name": "CMV hyperimmune globulin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "The George Washington University Biostatistics Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 399,
      "start_date": "2012-04",
      "completion_date": "2021-06-30",
      "has_results": true,
      "last_update_posted_date": "2023-02-02",
      "last_synced_at": "2026-09-29T11:45:01.680Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Stanford, California • Aurora, Colorado + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01376778"
    },
    {
      "nct_id": "NCT01951716",
      "title": "Effects of Xenin-25 on Insulin Secretion and Gastric Emptying in Humans With and Without a Complete Truncal Vagotomy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Does the Vagus Nerve Mediate the Effects of Xenin-25"
      ],
      "interventions": [
        {
          "name": "Graded Glucose Infusion with Placebo",
          "type": "DRUG"
        },
        {
          "name": "Graded Glucose Infusion with GIP Alone",
          "type": "DRUG"
        },
        {
          "name": "Graded Glucose Infusion with xenin-25 alone",
          "type": "DRUG"
        },
        {
          "name": "Graded Glucose Infusion with GIP plus xenin-25",
          "type": "DRUG"
        },
        {
          "name": "Meal Tolerance Test with Placebo",
          "type": "DRUG"
        },
        {
          "name": "Meal Tolerance Test with xenin-25",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 0,
      "start_date": "2013-01",
      "completion_date": "2018-07",
      "has_results": false,
      "last_update_posted_date": "2018-04-26",
      "last_synced_at": "2026-09-29T11:45:01.680Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01951716"
    },
    {
      "nct_id": "NCT00818662",
      "title": "A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer´s Disease"
      ],
      "interventions": [
        {
          "name": "Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo solution: Human Albumin 0.25% - 4 mL/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo solution: Human Albumin 0.25% - 2 mL/kg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "50 Years to 89 Years"
      },
      "enrollment_count": 390,
      "start_date": "2008-12-19",
      "completion_date": "2012-12-10",
      "has_results": true,
      "last_update_posted_date": "2021-05-19",
      "last_synced_at": "2026-09-29T11:45:01.680Z",
      "location_count": 37,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00818662"
    },
    {
      "nct_id": "NCT01951729",
      "title": "The Role of Cholinergic Signaling for Mediating the Effects of GIP and/or Xenin-25 on Insulin Secretion",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pre-diabetes"
      ],
      "interventions": [
        {
          "name": "Control",
          "type": "DRUG"
        },
        {
          "name": "Xenin-25 without atropine",
          "type": "DRUG"
        },
        {
          "name": "GIP without atropine",
          "type": "DRUG"
        },
        {
          "name": "Placebo with atropine",
          "type": "DRUG"
        },
        {
          "name": "Xenin-25 with atropine",
          "type": "DRUG"
        },
        {
          "name": "GIP with atropine",
          "type": "DRUG"
        },
        {
          "name": "GIP plus Xenin-25 without atropine",
          "type": "DRUG"
        },
        {
          "name": "GIP plus Xenin-25 with atropine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 15,
      "start_date": "2013-03-13",
      "completion_date": "2015-05",
      "has_results": false,
      "last_update_posted_date": "2018-05-25",
      "last_synced_at": "2026-09-29T11:45:01.680Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01951729"
    },
    {
      "nct_id": "NCT02675556",
      "title": "Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Treatment Resistant Depression"
      ],
      "interventions": [
        {
          "name": "Allo-hMSCs",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Joshua M Hare",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 1,
      "start_date": "2017-10-31",
      "completion_date": "2019-03-26",
      "has_results": false,
      "last_update_posted_date": "2019-04-01",
      "last_synced_at": "2026-09-29T11:45:01.680Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02675556"
    },
    {
      "nct_id": "NCT00220779",
      "title": "Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified",
          "type": "DRUG"
        },
        {
          "name": "Albumin (Human) 25%, United States Pharmacopeia (USP)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 128,
      "start_date": "2002-12",
      "completion_date": "2005-02",
      "has_results": true,
      "last_update_posted_date": "2016-04-27",
      "last_synced_at": "2026-09-29T11:45:01.680Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • New York, New York + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Stony Brook",
          "state": "New York"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00220779"
    },
    {
      "nct_id": "NCT00606437",
      "title": "Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Myeloma",
        "Leukemia",
        "Myelodysplasia",
        "Solid Tumors",
        "Hodgkin's Disease",
        "Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Total Body Irradiation with Fludarabine in UCB Transplants",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "14 Years to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2005-09",
      "completion_date": "2014-02",
      "has_results": false,
      "last_update_posted_date": "2014-05-16",
      "last_synced_at": "2026-09-29T11:45:01.680Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00606437"
    },
    {
      "nct_id": "NCT04390399",
      "title": "Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "N-803",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aldoxorubicin HCl",
          "type": "DRUG"
        },
        {
          "name": "PD-L1 t-haNK",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "5-Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "SBRT",
          "type": "PROCEDURE"
        },
        {
          "name": "Irinotecan liposome",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 328,
      "start_date": "2020-07-21",
      "completion_date": "2026-05-31",
      "has_results": false,
      "last_update_posted_date": "2025-12-15",
      "last_synced_at": "2026-09-29T11:45:01.680Z",
      "location_count": 4,
      "location_summary": "El Segundo, California • Newport Beach, California • East Brunswick, New Jersey + 1 more",
      "locations": [
        {
          "city": "El Segundo",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "East Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Sioux Falls",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04390399"
    },
    {
      "nct_id": "NCT03563170",
      "title": "QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma Non-resectable",
        "Hepatocellular Carcinoma Recurrent"
      ],
      "interventions": [
        {
          "name": "ETBX-011",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GI-4000",
          "type": "BIOLOGICAL"
        },
        {
          "name": "haNK for infusion",
          "type": "BIOLOGICAL"
        },
        {
          "name": "avelumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "5-Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "nab-Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        },
        {
          "name": "SBRT",
          "type": "PROCEDURE"
        },
        {
          "name": "Aldoxorubicin hydrochloride",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ETBX-051",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ETBX-061",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GI-6207",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GI-6301",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "N-803",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2018-05-25",
      "completion_date": "2019-08-23",
      "has_results": false,
      "last_update_posted_date": "2021-03-18",
      "last_synced_at": "2026-09-29T11:45:01.680Z",
      "location_count": 1,
      "location_summary": "El Segundo, California",
      "locations": [
        {
          "city": "El Segundo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03563170"
    },
    {
      "nct_id": "NCT02715531",
      "title": "A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "5-FU",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Nab-Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 243,
      "start_date": "2016-04-06",
      "completion_date": "2021-05-31",
      "has_results": false,
      "last_update_posted_date": "2021-07-09",
      "last_synced_at": "2026-09-29T11:45:01.680Z",
      "location_count": 12,
      "location_summary": "Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 8 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02715531"
    }
  ]
}